Medchemexpress LLC Navlimetostat hydrochloride | 2630904-45-7 | MFCD34604075 | 99.61% | 501.34 | 50 MG

Supplier:  Medchemexpress LLC HY139611C50MG

Navlimetostat hydrochloride, also known as MRTX-1719 hydrochloride, is a potent, orally active, selective PRMT5-MTA complex inhibitor (IC50 values of 3.6 nM for PRMT5-MTA and 20.5 nM for PRMT5). It binds strongly to the PRMT5-MTA complex (KD of 0.14 pM) and demonstrates antineoplastic activity in vitro and in vivo, making it suitable for cancer research.

• In vitro activity: Inhibits PRMT5 activity (IC50 8 nM) and viability (IC50 12 nM) in MTAP-deleted HCT116 cells.
• In vivo activity: Significantly reduces tumor growth in Lu-99 orthotopic xenograft models (12.5-100 mg/kg/day, oral, 21 days).
• Pharmacokinetics: High bioavailability in CD-1 mice (80% at 30 mg/kg p.o.) and Beagle dogs (59% at 10 mg/kg p.o.).

Catalog No. 50-003-48269